Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids

Clinical and Experimental Rheumatology

Volumn 31, Issue 4, 2013, Pages 498-505

  Cutolo Prof , M ^a   Iaccarino, L ^b   Doria, A ^b   Govoni, M ^c   Sulli, A ^a   Marcassa, C ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d IRCCS   (Italy)

Author keywords

Circadian rhythms; Glucocorticoids; Modified release; Morning stiffness; Rheumatoid arthritis

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; DAS28; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STANDARDIZATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; ISOXAZOLES; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE;

EID: 84883532182     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. SILMAN AJ, PEARSON JE: Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002; 4 (Suppl. 3): S265-72.
2. McINNES IB, O'DELL JR: State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1898-906.
3. SMOLEN JS, LANDEWÉ R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
4. FAVALLI EG, CAPORALI R, SINIGAGLIA L et al.: Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. Clin Exp Rheumatol 2011; 29 (Suppl. 66): S15-27.
5. BIJLSMA JW, SAAG KG, BUTTGEREIT F, DA SILVA JA: Developments in glucocorticoid therapy. Rheum Dis Clin North Am 2005; 31: 1-17, vii.
6. LONGUI CA: Glucocorticoid therapy: minimizing side effects. J Pediatr (Rio J) 2007; 83 (5 Suppl.): S163-77.
7. ZEN M, CANOVA M, CAMPANA C et al.: The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011; 10: 305-10.
8. JACOBS JW, BIJLSMA JW: Glucocorticoids in rheumatology: indications and routes of administration. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S81-4.
9. STREHL C, SPIES CM, BUTTGEREIT F: Pharmacodynamics of glucocorticoids. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S13-8.
10. SVENSSON B, BOONEN A, ALBERTSSON K, van der HEIJDE D, KELLER C, HAFSTROM I: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005; 52: 3360-70.
11. WASSENBERG S, RAU R, STEINFELD P, ZEIDLER H: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 3371-80.
12. ARVIDSON NG, GUDBJORNSSON B, ELFMAN L, RYDEN AC, TOTTERMAN TH, HALLGREN R: Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 521-4.
13. CUTOLO M, VILLAGGIO B, OTSA K, AAKRE O, SULLI A, SERIOLO B: Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease's symptoms. Autoimmun Rev 2005; 4: 497-502.
14. ARVIDSON NG, GUDBJORNSSON B, LARSSON A, HALLGREN R: The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis 1997; 56: 27-31.
15. CUTOLO M: Chronobiology and the treatment of rheumatoid arthritis. Curr Opin Rheumatol 2012; 24: 312-8.
16. SPIES CM, CUTOLO M, STRAUB RH, BURMESTER GR, BUTTGEREIT F: Prednisone chronotherapy. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S42-5.
17. BUTTGEREIT F, DOERING G, SCHAEFFLER A et al.: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008; 371: 205-14.
18. BUTTGEREIT F, DOERING G, SCHAEFFLER A et al.: Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1275-80.
19. PREVOO ML, Van't HOF MA, KUPER HH, van LEEUWEN MA, van de PUTTE LB, van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
20. FRANSEN J, van RIEL PL: Outcome measures in inflammatory rheumatic diseases. Arthritis Res Ther 2009; 11: 244.
21. WELLS G, BECKER JC, TENG J et al.: Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
22. FRANSEN J, van RIEL PL: The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 2009; 35: 745-57, vii-viii.
23. SZEFLER SJ, EBLING WF, GEORGITIS JW, JUSKO WJ: Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. Eur J Clin Pharmacol 1986; 30: 323-9.
24. CHROUSOS GP: Adrenocorticosteroids & Adrenocortical Antagonists. In: KATZUNG BG (Ed.) Basic & Clinical Pharmacology, 10th edition: McGraw-Hill Medical; 2007. p. 635-52.
25. STAVREVA DA, WIENCH M, JOHN S et al.: Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat Cell Biol 2009; 11: 1093-102.
26. PINCUS T, SWEARINGEN CJ, LUTA G, SOKKA T: Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 2009; 68: 1715-20.
27. CUTOLO M: Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol 2011; 7: 500-2.
28. GORTER SL, BIJLSMA JW, CUTOLO M et al.: Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1010-4.
29. BUTTGEREIT F, MEHTA D, KIRWAN J et al.: Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2012.
30. MORRISON E, CROSBIE D, CAPELL HA: Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. Rheumatology (Oxford) 2003; 42: 1247-50.
31. SILVERMAN SL: From randomized controlled trials to observational studies. Am J Med 2009; 122: 114-20.
32. CUTOLO M, BUTTGEREIT F, STRAUB RH: Regulation of glucocorticoids by the central nervous system. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S19-22.
33. PINCUS T, BIJLSMA JW, BRAUN J, BUTTGEREIT F, CUTOLO M: Low-dose glucocorticoids in rheumatic diseases: introduction. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S2-4.